Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial
Conditions
Interventions
Thermosensitive Nanogel Embolic Agent
Locations
1
China
Gao-Jun Teng
Nanjing, China
Start Date
September 10, 2024
Primary Completion Date
April 30, 2026
Completion Date
April 30, 2026
Last Updated
September 19, 2024
NCT07175441
NCT05096715
NCT07141056
NCT06911255
NCT06788353
NCT07480382
Lead Sponsor
Zhongda Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions